お知らせ • Jan 21
Cytophage Technologies Ltd. Announces Chief Financial Officer Changes Cytophage Technologies Ltd. announced the appointment of James Kinley, CPA CA, as Chief Financial Officer. Mr. Kinley is based in Winnipeg and brings extensive experience in the biotech industry, having served as a CFO to several publicly listed healthcare companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. He will work with management and the Board of Directors to ensure continued compliance with the Company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the Company will also be able to benefit from cost savings in the appointment of Mr. Kinley. Mr. Kinley replaces Julius Kalcevich who has been the Company’s CFO since July 2023. Mr. Kalcevich was brought on to take the Company public through a reverse takeover and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting, and public company compliance during the transition period. Mr. Kalcevich will remain available to the Company as an ad-hoc independent consultant. お知らせ • Nov 29
Cytophage Technologies Ltd. announced that it has received CAD 1.2 million in funding On November 28, 2025, the company has closed the transaction. The company has issued 990,000 Units at a price of CAD 0.2 per unit for aggregate proceeds of CAD198,000. In connection with the closing, the Company has also agreed, subject to receiving Exchange approval, to pay finder’s fees of CAD4,200 in cash and to 21,000 broker warrants, on the same terms as the Warrants forming part of the Offering, to qualified non related parties. The closing of the Offering remains subject to all regulatory approvals from the TSX Venture Exchange. お知らせ • Oct 17
Cytophage Technologies Ltd. announced that it expects to receive CAD 1.2 million in funding Cytophage Technologies Ltd. announced a non-brokered private placement of up to 6,000,000 units at CAD 0.20 per Unit , for gross proceeds of up to CAD 1,200,000. Each Unit consists of one common share of the Company and one half of a common share purchase warrant. Each whole Warrant entitles the holder thereof to purchase one additional Share at a price of CAD 0.40 per Warrant Share, for a period of 24 months from the date of issuance. The Company reserves the right to increase the size of the Offering by up to an additional CAD 600,000 through the sale of up to 3,000,000 additional Units. All securities issued under the Offering, including Warrant Shares issuable upon exercise of the warrants and finders warrant shares issuable upon exercise of the Finders Warrants, will be subject to a hold period expiring 4 months and 1 day after each applicable closing date, in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws. The Company may close the Offering in multiple tranches. With the pending regulatory approvals from the TSX Venture Exchange, the Company expects to close the Offering on or about November 6, 2025. お知らせ • Jun 11
Cytophage Technologies Ltd. announced that it has received CAD 1.55 million in funding On June 10, 2025, Cytophage Technologies Ltd. closed the transaction. In connection with offering company paid pay finders' fees of CAD 27,545 in cash and issue 128,975 broker warrants. All securities issued are subject to a four-month hold period expiring Oct. 11, 2025.The company's directors and senior officers have collectively subscribed for 1,212,500 units for CAD 242,500, representing approximately 15.7 per cent of the total offering. お知らせ • May 14
Cytophage Technologies Ltd. announced that it expects to receive CAD 1 million in funding Cytophage Technologies Ltd announced a non brokered private placement to issue 5,000,000 units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 1,000,000 on May 14, 2025. Each unit consists of one common share of the company and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.4 per warrant share for a period of 24 months from the date of issuance. The company has received commitments from its directors and officers to subscribe for approximately 1,000,000 units, for gross proceeds of approximately CAD 200,000. The company anticipates closing the offering in multiple tranches. Pending all regulatory approvals from the TSX Venture Exchange, the company expects to close the first tranche of the offering on or about May 22, 2025. The company may pay finder’s fees of up to 7% of gross proceeds raised and issue warrants, on the same terms as the Warrants forming part of the units, of up to 7% of the number of units sold to investors, to qualified non-related parties, in accordance with the policies of the exchange. All securities issued under the offering, including warrant shares issuable on exercise of the Warrants, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws. お知らせ • Apr 30
Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025 Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025.